ARKG vs. GNOM

Last updated Jun 24, 2026

ARKG (ARK Genomic Revolution Multi-Sector ETF) and GNOM (Global X Genomics & Biotechnology ETF) are both Health & Biotech Equities funds. ARKG is actively managed, while GNOM is passively managed. Over the past 5 years, ARKG returned -16.56%/yr vs -11.06%/yr for GNOM. Their correlation of 0.89 suggests significant overlap in exposure. ARKG charges 0.75%/yr vs 0.50%/yr for GNOM.

Performance

ARKG vs. GNOM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ARK Genomic Revolution Multi-Sector ETF (ARKG) and Global X Genomics & Biotechnology ETF (GNOM). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, ARKG achieves a 24.30% return, which is significantly higher than GNOM's 14.90% return.

ARKG

• 1D: -1.07%
• 1M: 17.41%
• YTD: 24.30%
• 6M: 19.48%
• 1Y: 52.71%
• 3Y*: 3.17%
• 5Y*: -16.56%
• 10Y*: 8.67%

GNOM

• 1D: 0.90%
• 1M: 12.22%
• YTD: 14.90%
• 6M: 11.42%
• 1Y: 61.83%
• 3Y*: 2.88%
• 5Y*: -11.06%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

ARKG vs. GNOM - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
ARKG ARK Genomic Revolution Multi-Sector ETF	24.30%	23.04%	-28.24%	16.22%	-53.90%	-33.92%	180.40%	2.07%
GNOM Global X Genomics & Biotechnology ETF	14.90%	18.65%	-15.99%	-8.63%	-36.27%	-15.93%	51.52%	2.03%

Correlation

The correlation between ARKG and GNOM is 0.85, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.85
Correlation (3Y) Calculated over the trailing 3-year period	0.88
Correlation (5Y) Calculated over the trailing 5-year period	0.91
Correlation (All Time) Calculated using the full available price history since Apr 10, 2019	0.89

The correlation between ARKG and GNOM has been stable across timeframes, ranging from 0.85 to 0.91 - a consistent structural relationship.

ARKG vs. GNOM - Sectors Allocation Comparison

Sectors	ARKG	GNOM
Healthcare	99.3%	99.7%
Financial Services	0.5%	-
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Industrials	-	-
Real Estate	-	-
Technology	-	0.3%
Utilities	-	-

Return for Risk

ARKG vs. GNOM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ARKG

ARKG Risk / Return Rank: 36
ARKG Sharpe Ratio Rank: 36
ARKG Sortino Ratio Rank: 38
ARKG Omega Ratio Rank: 34
ARKG Calmar Ratio Rank: 40
ARKG Martin Ratio Rank: 32

GNOM

GNOM Risk / Return Rank: 68
GNOM Sharpe Ratio Rank: 76
GNOM Sortino Ratio Rank: 74
GNOM Omega Ratio Rank: 63
GNOM Calmar Ratio Rank: 71
GNOM Martin Ratio Rank: 58

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ARKG vs. GNOM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ARK Genomic Revolution Multi-Sector ETF (ARKG) and Global X Genomics & Biotechnology ETF (GNOM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	ARKG	GNOM	Difference
Sharpe ratio: Return per unit of total volatility	1.25	2.28	-1.03
Sortino ratio: Return per unit of downside risk	1.91	3.11	-1.19
Omega ratio: Gain probability vs. loss probability	1.22	1.36	-0.14
Calmar ratio: Return relative to maximum drawdown	1.93	3.42	-1.49
Martin ratio: Return relative to average drawdown	4.58	9.81	-5.23

ARKG vs. GNOM - Sharpe Ratio Comparison

The current ARKG Sharpe Ratio is 1.25, which is lower than the GNOM Sharpe Ratio of 2.28. The chart below compares the historical Sharpe Ratios of ARKG and GNOM, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

ARKG vs. GNOM - Drawdown Comparison

The maximum ARKG drawdown since its inception was -83.59%, which is greater than GNOM's maximum drawdown of -75.00%. Use the drawdown chart below to compare losses from any high point for ARKG and GNOM.

Drawdown Indicators

	ARKG	GNOM	Difference
Max Drawdown Largest peak-to-trough decline	-83.59%	-75.00%	-8.59%
Max Drawdown (1Y) Largest decline over 1 year	-27.51%	-18.17%	-9.34%
Max Drawdown (3Y) Largest decline over 3 years	-51.96%	-44.24%	-7.72%
Max Drawdown (5Y) Largest decline over 5 years	-80.18%	-72.29%	-7.89%
Max Drawdown (10Y) Largest decline over 10 years	-83.59%	—	—
Current Drawdown Current decline from peak	-67.78%	-52.52%	-15.26%
Average Drawdown Average peak-to-trough decline	-36.02%	-40.63%	+4.61%
Ulcer Index Depth and duration of drawdowns from previous peaks	11.53%	6.32%	+5.21%

Volatility

ARKG vs. GNOM - Volatility Comparison

ARK Genomic Revolution Multi-Sector ETF (ARKG) has a higher volatility of 15.19% compared to Global X Genomics & Biotechnology ETF (GNOM) at 9.34%. This indicates that ARKG's price experiences larger fluctuations and is considered to be riskier than GNOM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ARKG	GNOM	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.19%	9.34%	+5.85%
Volatility (6M) Calculated over the trailing 6-month period	30.91%	20.57%	+10.34%
Volatility (1Y) Calculated over the trailing 1-year period	42.54%	27.29%	+15.25%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	45.93%	33.68%	+12.25%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	41.29%	34.17%	+7.12%

ARKG vs. GNOM - Expense Ratio Comparison

ARKG has a 0.75% expense ratio, which is higher than GNOM's 0.50% expense ratio.

Dividends

ARKG vs. GNOM - Dividend Comparison

ARKG has not paid dividends to shareholders, while GNOM's dividend yield for the trailing twelve months is around 1.20%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017
ARKG ARK Genomic Revolution Multi-Sector ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.62%	0.85%	3.14%	0.82%	1.34%
GNOM Global X Genomics & Biotechnology ETF	1.20%	1.37%	0.00%	0.00%	0.00%	0.03%	0.14%	0.00%	0.00%	0.00%

Frequently Asked Questions

Can I hold both ARKG and GNOM in my portfolio?

ARKG and GNOM have a correlation of 0.85, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, ARKG or GNOM?

ARKG has higher volatility (15.19%) compared to GNOM (9.34%). In terms of maximum drawdown, ARKG dropped -83.59% vs GNOM's -75.00%.

Which ETF is better, ARKG or GNOM?

On 5-year performance, GNOM leads with -11.06% vs -16.56% for ARKG. On fees, GNOM is cheaper at 0.50% per year. On volatility, GNOM has been the lower-risk option at 9.34%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, ARKG or GNOM?

Over the 5-year period, GNOM has performed better with a -11.06% return vs -16.56%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, ARKG or GNOM?

GNOM is cheaper with a 0.50% expense ratio, compared with 0.75% for ARKG.

Which ETF pays a higher dividend yield, ARKG or GNOM?

GNOM has the higher dividend yield at 1.20%, compared with 0.00% for ARKG.

What is the main difference between ARKG and GNOM?

They also come from different issuers: ARK and Global X. Their fees differ too: 0.75% for ARKG and 0.50% for GNOM.

Which has better risk-adjusted returns?

GNOM currently has the higher Sharpe Ratio (2.28 vs 1.25), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.